Mesoblast Ltd. buy stratec
Start price
22.12.17
/
50%
€1.05
Target price
24.12.18
€1.50
Performance (%)
-40.42%
End price
24.12.18
€0.63
Summary
This prediction ended on 24.12.18 with a price of €0.63. Massive losses of -40.42% were the result for the BUY prediction by stratec. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Mesoblast Ltd. | -3.704% | -3.704% | 1.563% | -43.650% |
| iShares Core DAX® | -1.226% | 2.804% | 14.933% | 16.561% |
| iShares Nasdaq 100 | -1.845% | 2.732% | 26.075% | 54.743% |
| iShares Nikkei 225® | -1.132% | -2.218% | 5.361% | 4.560% |
| iShares S&P 500 | -0.980% | 1.883% | 22.727% | 45.760% |
Comments by stratec for this prediction
In the thread Mesoblast Ltd. diskutieren
Mesoblast advances toward the end game in GVHD
News: MESO announced that they have completed enrollment of their Phase 3 trial investigating the allogeneic mesenchymal stem cell product Prochymal in acute GVHD. They hope to have top line data
results in early 2018, possibly as soon as Q1.
Looking forward: GVHD (Acute, steroid-refractory graft-versus-host disease) at any stage and at any timing continues to represent a serious unmet need. With the approval of ibrutinib, however clinicians gained a potent, new weapon against chronic GVHD. But acute disease remains a serious challenge, especially when steroids don't work. Hopefully, MESO is on the fast track with Prochymal, and one have to look forward to top line results in the near future.
The comment has been deleted